Vidaza and Dacogen Improve Overall Survival Of MDS Patients (EHA 2009)
Published: Jun 12, 2009 9:50 am
Israeli researchers presented the effectiveness of hypomethylating agents Vidaza (azacitidine) and Dacogen (decitabine) on improving overall survival of myelodysplastic syndromes (MDS) patients. This information was presented at the European Hematology Association (EHA) 14th Congress in Berlin.
Methyl groups that are bound to DNA sequences cause problems by preventing the regulation of cellular growth and causing uncontrollable cell division. Hypomethylating or demethylating agents, like Vidaza or Dacogen, allow the DNA sequences to function normally by removing these problematic methyl groups.
Researchers found four relevant randomized controlled trials, but only evaluated three, which compared 952 patients who received either hypomethylating agents or supportive care. Supportive care, such as blood transfusions and antibiotics, does not cure MDS or prevent acute myeloid leukemia (AML) transformation, but treats symptoms caused by low blood cell counts known as cytopenias. Stem cell transplantation is currently the only therapy able to generate complete recovery from MDS. This study evaluated Vidaza and Dacogen with respect to non-curative treatments.
The study evaluated overall survival, length of time to AML or death, complete or partial response, and severity of side effects. A complete response, as measured by the 2000 International Working Group (IWG) criteria, is defined by having a blood count of more than 1,000 neutrophil per µL and more than 100,000 platelets per µL. Evaluation of two of the four studies consisting of 549 patients showed treatment with Vidaza resulted in longer overall survival time than treatment with supportive care. However, one of the trials with 233 patients taking Dacogen did not show this same overall survival advantage.
An overview of all three evaluated studies and a fourth study abstract concluded that hypomethylating agents significantly lengthened the progression time to AML or death, improved the number of complete or partial responses, and resulted in few side effects.
For more information, see abstract 0261 from the “Myelodysplastic syndromes I” session of the 14th Congress of the EHA.
- Vidaza and Dacogen Effective In Myelodysplastic Syndromes Patients With Decreased Kidney Function (ASCO 2009)
- Study Finds Dacogen And Vidaza Better Than Conventional Care For MDS Patients
- Vidaza And Dacogen Therapy Before Stem Cell Transplantation Is Effective And Safe In MDS Patients
- Practical Questions And Answers For Patients With MDS Starting Vidaza Or Dacogen Treatment
- MDS Patients Taking Dacogen May Require Fewer Transfusions Than Patients Taking Vidaza